All News
Putting IL17i into ‘focus’ for SpA-associated uveitis
The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol.
Other data have emerged for JAKi and IL17i, with respect to acute anterior uveitis.
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality:
- Lower income & education,
- No partner
- On sick leave/disability benefits
@RheumNow https://t.co/hgEfJzoqNg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC
Links:
Dr. John Cush RheumNow ( View Tweet)
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
David Liew drdavidliew ( View Tweet)
#neuromodulation in #rheumatoid #arthritis
What is it?
👇
Autonomic & immune system interaction
Who seeks this Rx?
desperate pts w pain
No Rx left
Interested in technology
#EULAR2025 @RheumNow @eular_org
#D2T #RA https://t.co/XWWFiUK6Em
Links:
Janet Pope Janetbirdope ( View Tweet)
#vagal & #splenic #nerves most studied
In #immune #system interaction
#PNS can detect #inflammation
use in #D2T #RA w active disease ?
Key factors in #neurostimulation - many
#EULAR2025 @RheumNow @eular_org
#D2T in #RA session https://t.co/tCgpGtI5z2
Links:
Janet Pope Janetbirdope ( View Tweet)
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases?
A thread 🧵👇🏼
@RheumNow #EULAR2025 https://t.co/KLZN9MvcFy
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up.
Would you rather be addicted to prescription opioids or recreational cannabis?
(not going to argue about cannabis addiction - let’s say social impact is equal)
@RheumNow
David Liew drdavidliew ( View Tweet)
#Vagal #nerve #stimulation
Hand held device
#BDMARD failure
Plausible - improved pro inflammatory cytokines
wears off benefit if stopped
Attenuates in ~half over yrs
Open label uncontrolled
@RheumNow @eular_org #EULAR2025
Session D2T-RA https://t.co/98K5gwasHv
Links:
Janet Pope Janetbirdope ( View Tweet)
#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts
RESSET RCT
+RA #RCT w #VNS
But low response with stat significance
ACR20 1/4 sham vs 1/3 VNS
Would add on to new SoC? 🤔
#EULAR2025 @RheumNow #eular_org
#D2T- RA-session https://t.co/tR1pLPBr74
Links:
Janet Pope Janetbirdope ( View Tweet)
So we used to get taught about bimodal age distribution of RA onset - young people and old people.
Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity
Global Burden of Disease data
#EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy
David Liew drdavidliew ( View Tweet)
Prédiction of PsA from PsO. Stockholm cohort, n=672):
•PsA incidence 21.1/1000 PY.
•AUC 0.80 for both referral and prognostic models.
•Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA.
•Early identification feasible.
Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1
David Liew drdavidliew ( View Tweet)
Study on the HLAs associated with the occurrence and course of acute/tender dactylitis in PsA patients.
Acute dactylitis genetics:
•HLA-B27 (OR 1.71), HLA-C12 (OR 1.43), B38/C12 & B27/C02 haplotypes.
•Resolution faster on b/tsDMARDs (HR 1.67); unaffected by HLA.
Abstract
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
cool stuff at #EULAR2025
RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in
#RA w 1or >1 #bDMARD-IR
N=242
D/C bDMARD,
on #csDMARD
#RA 12 yrs, 10SJC 12TJC
2.6 b/tsDMARD failure
Wk12 EULAR good/mod response
61v 42%
Sham▶️goes VNS ✅data=
@RheumNow @eular_org abst#OP190
Janet Pope Janetbirdope ( View Tweet)
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j
Dr. John Cush RheumNow ( View Tweet)
